US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Kailera Therapeutics / Equity Capital Markets

<ul>
<li>IPO Momentum Reverses: KLRA opened 62.5% above issue but has subsequently declined 58.6% from its first trade, closing October 13 at $10.77.</li>
<li>Clinical Progress Continues: Kailera has completed enrollment in its Phase 3 ribupatide obesity trial, providing an important milestone despite the stock's weakness.</li>
<li>Investor Patience Tested: Significant private-market backing has not prevented selling pressure, while potential early-investor liquidity remains an overhang.</li>
</ul>


IPO Momentum Reverses: KLRA opened 62.5% above issue but has subsequently declined 58.6% from its first trade, closing October 13 at $10.77.
Clinical Progress Continues: Kailera has completed enrollment in its Phase 3 ribupatide obesity trial, providing an important milestone despite the stock's weakness.
Investor Patience Tested: Significant private-market backing has not prevented selling pressure, while potential early-investor liquidity remains an overhang.


Kailera Therapeutics (KLRA): Post-180-Day Review: Heavyweight Backers, Lightweight Returns

<ul>
<li>Kailera Therapeutics priced upsized IPO at $16 and surged 62.5% on debut, opening at $26 with strong institutional demand and tight trading range.</li>
<li>Oversubscribed deal with concentrated allocations, signaling strong conviction from top-tier investors and disciplined bookbuilding by syndicate and management.</li>
<li>Lead obesity pipeline and Phase 3 ribupatide asset support long-term growth narrative in a structurally expanding global obesity therapeutics market.</li>
</ul>


Kailera Therapeutics priced upsized IPO at $16 and surged 62.5% on debut, opening at $26 with strong institutional demand and tight trading range.
Oversubscribed deal with concentrated allocations, signaling strong conviction from top-tier investors and disciplined bookbuilding by syndicate and management.
Lead obesity pipeline and Phase 3 ribupatide asset support long-term growth narrative in a structurally expanding global obesity therapeutics market.


Kailera Therapeutics (KLRA): Strong Appetite Fuels Kailera IPO Surge, Opens with Ten Point Premium

<ul>
<li>Kailera Therapeutics IPO demand is multiple-times oversubscribed, signaling strong institutional interest and potential pricing strength ahead of its expected Friday debut.</li>
<li>Lead asset ribupatide in Phase 3 targets best-in-class weight loss, supported by a diversified GLP-1 pipeline spanning oral and injectable therapies.</li>
<li>Backed by top-tier investors and led by a proven CEO with major biotech exits, positioning the company for strong execution and potential long-term value creation.</li>
</ul>


Kailera Therapeutics IPO demand is multiple-times oversubscribed, signaling strong institutional interest and potential pricing strength ahead of its expected Friday debut.
Lead asset ribupatide in Phase 3 targets best-in-class weight loss, supported by a diversified GLP-1 pipeline spanning oral and injectable therapies.
Backed by top-tier investors and led by a proven CEO with major biotech exits, positioning the company for strong execution and potential long-term value creation.


Kailera Therapeutics (KLRA): Bain Backed Obesity Biotech Garners Significant Interest

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>✅ IPO PROPHET RATING: 7.72/10 🏦 Deal Quality &amp; Underwriters: 8.4/10 Kailera Therapeutics is on the roadshow, marketing approximately 33.3 million shares at $14 to $16, targeting over $500 million in proceeds and a valuation approaching $1.8–$1.9 billion.</li><li>The company is focused on GLP-1–based obesity treatments, with a lead asset in late-stage clinical trials and additional oral and injectable programs in development.</li><li>The deal is being marketed into a reopening biotech IPO environment with participation from large institutional investors.</li></ul>

✅ IPO PROPHET RATING: 7.72/10 🏦 Deal Quality &amp; Underwriters: 8.4/10 Kailera Therapeutics is on the roadshow, marketing approximately 33.3 million shares at $14 to $16, targeting over $500 million in proceeds and a valuation approaching $1.8–$1.9 billion.The company is focused on GLP-1–based obesity treatments, with a lead asset in late-stage clinical trials and additional oral and injectable programs in development.The deal is being marketed into a reopening biotech IPO environment with participation from large institutional investors.

<ul><li>Kailera Therapeutics is moving toward the public markets with plans to offer 33.3 million shares at a range of $14 to $16 , implying a midpoint deal size of approximately $500 million and a post-offer market cap of roughly $1.8 billion , as the clinical-stage biotechnology company looks to position itself in the rapidly expanding obesity therapeutics market.</li><li>The company has applied to list on the Nasdaq Global Select Market under the ticker “KLRA” , with J.P.</li><li>Morgan, Jefferies, Leerink Partners, TD Cowen, and Evercore ISI serving as joint bookrunners.</li></ul>

Kailera Therapeutics is moving toward the public markets with plans to offer 33.3 million shares at a range of $14 to $16 , implying a midpoint deal size of approximately $500 million and a post-offer market cap of roughly $1.8 billion , as the clinical-stage biotechnology company looks to position itself in the rapidly expanding obesity therapeutics market.The company has applied to list on the Nasdaq Global Select Market under the ticker “KLRA” , with J.P.Morgan, Jefferies, Leerink Partners, TD Cowen, and Evercore ISI serving as joint bookrunners.

Kailera Targets ~$500M IPO to Challenge GLP-1 Leaders with Next-Gen Obesity Pipeline

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kailera Therapeutics (KLRA US)

Kailera Therapeutics (KLRA): Post-180-Day Review: Heavyweight Backers, Lightweight Returns

KLRA's 62.5% IPO opening premium has vanished, with shares 33% below issue. Phase 3 enrollment is complete, but investor patience and aftermarket...

IPO Boutique

Kailera Therapeutics (KLRA): Strong Appetite Fuels Kailera IPO Surge, Opens with Ten Point Premium

Kailera Therapeutics IPO prices at $16, surges 62.5% on debut with strong institutional demand and promising obesity pipeline for long-term growth.

IPO Boutique

Kailera Therapeutics (KLRA): Bain Backed Obesity Biotech Garners Significant Interest

Kailera Therapeutics IPO sees strong demand, with potential for pricing strength and long-term value creation driven by promising weight loss drug...

IPO Boutique

IPO Rating: Kailera Therapeutics, Inc.

✅ IPO PROPHET RATING: 7.72/10 🏦 Deal Quality & Underwriters: 8.4/10 Kailera Therapeutics is on the roadshow, marketing approximately 33.3...

IPO Prophet

Kailera Targets ~$500M IPO to Challenge GLP-1 Leaders with Next-Gen Obesity Pipeline

Kailera Therapeutics is moving toward the public markets with plans to offer 33.3 million shares at a range of $14 to $16 , implying a midpoint...

IPO Prophet

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Kailera Therapeutics (KLRA): Post-180-Day Review: Heavyweight Backers, Lightweight Returns

KLRA's 62.5% IPO opening premium has vanished, with shares 33% below issue. Phase 3 enrollment is complete, but investor patience and aftermarket...

IPO Boutique

Kailera Therapeutics (KLRA): Strong Appetite Fuels Kailera IPO Surge, Opens with Ten Point Premium

​Kailera Therapeutics IPO prices at $16, surges 62.5% on debut with strong institutional demand and promising obesity pipeline for long-term growth.

IPO Boutique

Kailera Therapeutics (KLRA): Bain Backed Obesity Biotech Garners Significant Interest

​Kailera Therapeutics IPO sees strong demand, with potential for pricing strength and long-term value creation driven by promising weight loss drug...

IPO Boutique

IPO Rating: Kailera Therapeutics, Inc.

✅ IPO PROPHET RATING: 7.72/10 🏦 Deal Quality & Underwriters: 8.4/10 Kailera Therapeutics is on the roadshow, marketing approximately 33.3...

IPO Prophet

Kailera Targets ~$500M IPO to Challenge GLP-1 Leaders with Next-Gen Obesity Pipeline

Kailera Therapeutics is moving toward the public markets with plans to offer 33.3 million shares at a range of $14 to $16 , implying a midpoint...

IPO Prophet

Kailera Therapeutics IPO prices at $16, surges 62.5% on debut with strong institutional demand and promising obesity pipeline for long-term growth.

Kailera Therapeutics IPO sees strong demand, with potential for pricing strength and long-term value creation driven by promising weight loss drug...